Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
SAN DIEGO, Feb. 14, 2017 -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) announced today that it will present at the 2nd Annual Disruptive Growth & Healthcare Conference at 11:15 AM Eastern Time (8:15 AM Pacific Time) on Wednesday, February 15, 2017. The presentation will take place in the Track 3 - Nolita room at the Convene in New York City. Dr. Marc Hedrick, CEO and President of Cytori Therapeutics, will provide an update on current corporate activities and recent developments. For those interested in attending, please visit www.DisruptNYC.com for more information.
A live audio and video webcast of the presentation will be available under the investor relations section of Cytori’s website at www.cytori.com (http://ir.cytori.com). A replay of the presentation will be available for 90 days following the event. Please connect to Cytori’s website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.
About Cytori Therapeutics
Cytori Therapeutics is a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. For more information: visit www.cytori.com.
Cytori Therapeutics, Inc. Tiago Girao, +1 (858) 458.0900 [email protected]
